相关实验视频

Updated: Jun 29, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

针对CD8的IL2通过恢复功能失调的T细胞池,在人类癌症组织中释放瘤特异性免疫力

Paulien Kaptein¹, Nadine Slingerland¹, Christina Metoikidou¹

¹Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Cancer discovery

|April 2, 2024

概括

一种新的CD8向IL2融合分子 (CD8-IL2) 有效地重新激活功能障碍的瘤特异性CD8+T细胞. 这种方法有望克服对PD-1阻断等当前癌症免疫疗法的耐药性.

科学领域:

免疫学免疫学免疫学
癌症生物学癌症生物学
分子疗法分子疗法

背景情况:

瘤特异性CD8+ T细胞对于抗瘤免疫是至关重要的,但在瘤微环境中经常变得功能失调.
免疫检查点阻塞 (ICB) 可以恢复T细胞功能,但许多患者没有反应,即使T细胞透.

研究的目的:

探索一种针对CD8的IL2融合分子 (CD8-IL2),用于内CD8+T细胞的选择性活性化.
评估CD8-IL2在克服T细胞功能障碍和对ICB抗性的有效性.

主要方法:

利用来自患者的瘤碎片来测试CD8-IL2融合分子.
研究了CD8-IL2在瘤微环境中的功能障碍的CD8+T细胞重新激活的能力.
将CD8-IL2与PD-1阻断的影响进行比较.

主要成果:

CD8-IL2治疗大大提高了内CD8+T细胞的效应能力.
通过CD8-IL2重新激活功能失调的T细胞需要同时识别抗原,并且优于PD-1阻断.
在抗PD-1疗法耐药的瘤中,CD8-IL2功能强化的T细胞.

结论:

CD8-IL2可选择性地重新激活功能失调的CD8+T细胞,增强抗瘤免疫力.
这种方法为癌症患者提供了潜在的新型治疗策略,特别是那些对现有的免疫疗法有耐药性的癌症患者.

更多相关视频

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...